Build Your Comparison

Side-by-side financial analysis
AEON logo
AEON
REVB logo
REVB
Try popular comparisons:

Stock Comparison

AEON vs REVB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AEON
AEON Biopharma, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$9M
5Y Perf.-99.9%
REVB
Revelation Biosciences, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$3M
5Y Perf.-100.0%

AEON vs REVB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AEON logoAEON
REVB logoREVB
IndustryBiotechnologyBiotechnology
Market Cap$9M$3M
Revenue (TTM)$0.00$0.00
Net Income (TTM)$-60M$-10M
Total Debt$36M$747K
Cash & Equiv.$3M$11M

AEON vs REVBLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AEON
REVB
StockJul 23Jun 26Return
AEON Biopharma, Inc. (AEON)1000.1-99.9%
Revelation Bioscien… (REVB)1000.0-100.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: AEON vs REVB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AEON and REVB are tied at the top with 2 categories each — the right choice depends on your priorities. Revelation Biosciences, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
AEON
AEON Biopharma, Inc.
The Income Pick

AEON has the current edge in this matchup, primarily because of its strength in income & stability and long-term compounding.

  • beta 0.11
  • -99.9% 10Y total return vs REVB's -100.0%
  • Lower volatility, beta 0.11, current ratio 0.49x
Best for: income & stability and long-term compounding
REVB
Revelation Biosciences, Inc.
The Growth Play

REVB is the clearest fit if your priority is growth exposure.

  • Rev growth -100.0%, EPS growth 72.7%
  • -100.0% revenue growth vs AEON's -135.5%
  • -88.0% ROA vs AEON's -7.0%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthREVB logoREVB-100.0% revenue growth vs AEON's -135.5%
Stability / SafetyAEON logoAEONBeta 0.11 vs REVB's 1.44
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)AEON logoAEON-18.1% vs REVB's -89.7%
Efficiency (ROA)REVB logoREVB-88.0% ROA vs AEON's -7.0%

AEON vs REVB — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLAEONLAGGINGREVB

Income & Cash Flow (Last 12 Months)

REVB leads this category, winning 1 of 1 comparable metric.

AEON and REVB operate at a comparable scale, with $0 and $0 in trailing revenue.

MetricAEON logoAEONAEON Biopharma, I…REVB logoREVBRevelation Biosci…
RevenueTrailing 12 months$0$0
EBITDAEarnings before interest/tax-$18M-$10M
Net IncomeAfter-tax profit-$60M-$10M
Free Cash FlowCash after capex-$12M-$9M
Gross MarginGross profit ÷ Revenue
Operating MarginEBIT ÷ Revenue
Net MarginNet income ÷ Revenue
FCF MarginFCF ÷ Revenue
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year-142.5%-28.4%
REVB leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

AEON leads this category, winning 1 of 1 comparable metric.
MetricAEON logoAEONAEON Biopharma, I…REVB logoREVBRevelation Biosci…
Market CapShares × price$9M$3M
Enterprise ValueMkt cap + debt − cash$41M-$7M
Trailing P/EPrice ÷ TTM EPS-0.18x-0.04x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue
Price / BookPrice ÷ Book value/share0.07x
Price / FCFMarket cap ÷ FCF
AEON leads this category, winning 1 of 1 comparable metric.

Profitability & Efficiency

REVB leads this category, winning 4 of 4 comparable metrics.

On the Piotroski fundamental quality scale (0–9), REVB scores 4/9 vs AEON's 2/9, reflecting mixed financial health.

MetricAEON logoAEONAEON Biopharma, I…REVB logoREVBRevelation Biosci…
ROE (TTM)Return on equity-107.7%
ROA (TTM)Return on assets-7.0%-88.0%
ROICReturn on invested capital
ROCEReturn on capital employed-126.9%
Piotroski ScoreFundamental quality 0–924
Debt / EquityFinancial leverage0.08x
Net DebtTotal debt minus cash$33M-$10M
Cash & Equiv.Liquid assets$3M$11M
Total DebtShort + long-term debt$36M$746,784
Interest CoverageEBIT ÷ Interest expense
REVB leads this category, winning 4 of 4 comparable metrics.

Total Returns (Dividends Reinvested)

AEON leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in AEON five years ago would be worth $11 today (with dividends reinvested), compared to $0 for REVB. Over the past 12 months, AEON leads with a -18.1% total return vs REVB's -89.7%. The 3-year compound annual growth rate (CAGR) favors AEON at -89.7% vs REVB's -94.6% — a key indicator of consistent wealth creation.

MetricAEON logoAEONAEON Biopharma, I…REVB logoREVBRevelation Biosci…
YTD ReturnYear-to-date-34.2%-69.3%
1-Year ReturnPast 12 months-18.1%-89.7%
3-Year ReturnCumulative with dividends-99.9%-100.0%
5-Year ReturnCumulative with dividends-99.9%-100.0%
10-Year ReturnCumulative with dividends-99.9%-100.0%
CAGR (3Y)Annualised 3-year return-89.7%-94.6%
AEON leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

AEON leads this category, winning 2 of 2 comparable metrics.

AEON is the less volatile stock with a 0.11 beta — it tends to amplify market swings less than REVB's 1.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AEON currently trades 50.4% from its 52-week high vs REVB's 7.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAEON logoAEONAEON Biopharma, I…REVB logoREVBRevelation Biosci…
Beta (5Y)Sensitivity to S&P 5000.11x1.44x
52-Week HighHighest price in past year$1.45$12.88
52-Week LowLowest price in past year$0.63$0.60
% of 52W HighCurrent price vs 52-week peak+50.4%+7.7%
RSI (14)Momentum oscillator 0–10033.741.8
Avg Volume (50D)Average daily shares traded85K62K
AEON leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricAEON logoAEONAEON Biopharma, I…REVB logoREVBRevelation Biosci…
Analyst RatingConsensus buy/hold/sell
Price TargetConsensus 12-month target
# AnalystsCovering analysts
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

AEON leads in 3 of 6 categories (Valuation Metrics, Total Returns). REVB leads in 2 (Income & Cash Flow, Profitability & Efficiency).

Best OverallAEON Biopharma, Inc. (AEON)Leads 3 of 6 categories
Loading custom metrics...

AEON vs REVB: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Which is the better long-term investment — AEON or REVB?

Over the past 5 years, AEON Biopharma, Inc.

(AEON) delivered a total return of -99. 9%, compared to -100. 0% for Revelation Biosciences, Inc. (REVB). Over 10 years, the gap is even starker: AEON returned -99. 9% versus REVB's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

02

Which is safer — AEON or REVB?

By beta (market sensitivity over 5 years), AEON Biopharma, Inc.

(AEON) is the lower-risk stock at 0. 11β versus Revelation Biosciences, Inc. 's 1. 44β — meaning REVB is approximately 1266% more volatile than AEON relative to the S&P 500.

03

Which is growing faster — AEON or REVB?

On earnings-per-share growth, the picture is similar: Revelation Biosciences, Inc.

grew EPS 72. 7% year-over-year, compared to -105. 4% for AEON Biopharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

04

Which has better profit margins — AEON or REVB?

AEON Biopharma, Inc.

(AEON) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Revelation Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEON leads at 0. 0% versus 0. 0% for REVB. At the gross margin level — before operating expenses — AEON leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — AEON or REVB?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

06

Is AEON or REVB better for a retirement portfolio?

For long-horizon retirement investors, AEON Biopharma, Inc.

(AEON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 11)). Both have compounded well over 10 years (AEON: -99. 9%, REVB: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between AEON and REVB?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.